急性髓系白血病(AML)患者骨髓白血病细胞上CD34高表达预示着短生存期和/或对大剂量化疗疗效差,同样骨髓增生异常综合征(MDS)患者骨髓及外周血中CD34阳性细胞增多与短生存期和转化为AML高危险性相关。作者使用流式细胞仪(FC)测定新鲜骨髓细胞悬液中CD34阳性细胞和免疫组织化学法(IH)测定石蜡包埋骨髓样本中CD34阳性细胞,并进行二种方法的比较。 受检患者分为三组:MDS组16例,其中难治性贫血3例,环状铁粒幼细胞性贫血5例,原始细胞过多性难治性贫血3例,转化中原始细胞过多性难治性贫血2例及慢性粒单核细胞白血病3例;AML组12例(M1 The high expression of CD34 on myeloid leukemia cells in patients with acute myeloid leukemia (AML) indicates a short survival time and/or poor efficacy on high-dose chemotherapy. Similarly, CD34-positive cells in bone marrow and peripheral blood of patients with myelodysplastic syndrome (MDS) are increasing. The short survival period is related to the high risk of conversion to AML. The authors used flow cytometry (FC) to measure CD34-positive cells in fresh bone marrow cell suspensions and immunohistochemistry (IH) to determine CD34-positive cells in paraffin-embedded bone marrow samples and performed a comparison of the two methods. Patients were divided into three groups: 16 patients in the MDS group, including 3 patients with refractory anemia, 5 patients with toroidal angiocytic anemia, and 3 patients with refractory anemia due to excessive cellular proliferation. 2 cases of refractory anemia and 3 cases of chronic myelomonocytic leukemia; 12 cases of AML group (M1